Macquarie Group Ltd. lessened its holdings in Allergan PLC. (NYSE:AGN) by 16.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 575,770 shares of the company’s stock after selling 113,958 shares during the period. Macquarie Group Ltd. owned about 0.17% of Allergan PLC. worth $139,963,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Howard Hughes Medical Institute acquired a new stake in shares of Allergan PLC. in the second quarter worth $103,000. Jacobi Capital Management LLC boosted its position in shares of Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares during the period. JNBA Financial Advisors boosted its position in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares during the period. Massey Quick & Co. LLC boosted its position in shares of Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after buying an additional 385 shares during the period. Finally, Pacific Center for Financial Services boosted its position in shares of Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after buying an additional 475 shares during the period. 82.04% of the stock is owned by institutional investors and hedge funds.

Shares of Allergan PLC. (NYSE AGN) opened at 204.08 on Friday. The firm has a 50 day moving average price of $216.44 and a 200-day moving average price of $232.29. The firm has a market cap of $68.23 billion, a PE ratio of 6.22 and a beta of 1.15. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the prior year, the business posted $3.35 EPS. The company’s quarterly revenue was up 8.8% on a year-over-year basis. On average, analysts predict that Allergan PLC. will post $16.21 EPS for the current fiscal year.

Allergan PLC. declared that its board has approved a share buyback program on Monday, September 25th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to repurchase up to 2.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were paid a dividend of $0.70 per share. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.37%. Allergan PLC.’s dividend payout ratio is 9.95%.

A number of research firms recently issued reports on AGN. Wells Fargo & Company set a $276.00 price objective on Allergan PLC. and gave the company a “buy” rating in a research report on Friday. Piper Jaffray Companies set a $227.00 price objective on Allergan PLC. and gave the company a “hold” rating in a research report on Friday. Cantor Fitzgerald set a $231.00 price objective on Allergan PLC. and gave the company a “hold” rating in a research report on Thursday. Cowen and Company reissued a “buy” rating on shares of Allergan PLC. in a research report on Thursday. Finally, Barclays PLC reissued an “equal weight” rating on shares of Allergan PLC. in a research report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $271.44.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/10/13/allergan-plc-agn-stake-lowered-by-macquarie-group-ltd.html.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.